Tiziana Life Sciences Ltd TLSA
0.62 USD +0.01 (+1.77%)
At closeNov 12, 2026, 4:32 AM EST
0.67 +0.05 +8.62%
Pre-market · Nov 12, 4:32 AM ET
0.61 Day range 0.6572
0.57 52-week range 1.90
- YTD
- -58.32%
- 1 year
- -64.31%
News
seekingalpha.com Tiziana Life Sciences Ltd (TLSA) Discusses Positive Phase 2a INFORM-MS Results for Intranasal Foralumab in Nonactive Secondary Progressive Multiple Sclerosis Transcript Tiziana Life Sciences Ltd (TLSA) Discusses Positive Phase 2a INFORM-MS Results for Intranasal Foralumab in Nonactive Secondary Progressive Multiple Sclerosis Transcript
benzinga.com Tiziana Life Sciences Highlights Phase 2a INFORM-MS Success For Intranasal Foralumab, Showing Reduced Neuroinflammation And Improved Fatigue In Secondary Progressive MS Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
globenewswire.com Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal Foralumab BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
globenewswire.com Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
benzinga.com Tiziana Life Sciences Announces Topline Data In Phase 2a INFORM-MS Trial With Intranasal Foralumab In Patients With Na-SPMS; Trial Meets Dual Primary Endpoints Trial met its dual primary endpoints for (1) statistically significant reduction (p=0.0168) in microglial activation as measured by TSPO PET imaging in patients treated with 50 ug nasal foralumab as…- benzinga.com Tiziana Life Sciences Begins Dosing Last Patient In Its Phase 2 Clinical Trial Evaluating Intranasal Foralumab In Patients With Early/Mild Alzheimer’s Disease; Topline Data Anticipated In Q1 2027 Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 93.3% to $2.03 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. Scinai Immunotherapeutics (NASDAQ:SCNI)…